BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul JL. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362-366. [PMID: 18287267 DOI: 10.2967/jnumed.107.044750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Furtado R, Crawford M, Sandroussi C. Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:2700-7. [DOI: 10.1245/s10434-014-3511-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
2 Ahmadzadehfar H, Habibi E, Ezziddin S, Wilhelm K, Fimmers R, Spengler U, Palmedo H, Strunk H, Schild HH, Biersack HJ, Risse J. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma: A single-center study based on a long-term follow-up. Nuklearmedizin 2018;53:46-53. [DOI: 10.3413/nukmed-0610-13-07] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, Shen F, Yan Z, Wu M. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010;17:3137-3144. [PMID: 20602260 DOI: 10.1245/s10434-010-1148-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
4 Ueno M, Uchiyama K, Ozawa S, Hayami S, Shigekawa Y, Tani M, Yamaue H. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624-3631. [PMID: 21614626 DOI: 10.1245/s10434-011-1800-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
5 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
6 Lintia-Gaultier A, Perret C, Ansquer C, Eugène T, Kraeber-Bodéré F, Frampas E. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years’ experience. Nucl Med Commun. 2013;34:674-681. [PMID: 23587835 DOI: 10.1097/mnm.0b013e32836141a0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9. [PMID: 20051971 DOI: 10.1038/nrgastro.2009.202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
8 Dumortier J, Decullier E, Hilleret MN, Bin-Dorel S, Valette PJ, Boillot O, Partensky C, Letoublon C, Ducerf C, Leroy V, Vuillez JP, Borson-Chazot F. Adjuvant Intraarterial Lipiodol or ¹³¹I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. J Nucl Med 2014;55:877-83. [PMID: 24722530 DOI: 10.2967/jnumed.113.131367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
9 Furtado RV, Ha L, Clarke S, Sandroussi C. Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma. J Oncol. 2015;2015:746917. [PMID: 26713092 DOI: 10.1155/2015/746917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Hong Y, Wu LP, Ye F, Zhou YM. Adjuvant Intrahepatic Injection Iodine-131-Lipiodol Improves Prognosis of Patients with Hepatocellular Carcinoma After Resection: a Meta-Analysis. Indian J Surg 2015;77:1227-32. [PMID: 27011542 DOI: 10.1007/s12262-015-1261-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25. [PMID: 26020026 DOI: 10.1159/000343878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gong L, Shi L, Sun J, Yuan WS, Chen JF, Liu P, Gong F, Dong JH. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Nucl Med Commun 2014;35:484-92. [PMID: 24492679 DOI: 10.1097/MNM.0000000000000081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
13 Zhong J, Zhong Q, Li L, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biol 2014;35:9459-68. [DOI: 10.1007/s13277-014-2443-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
14 Das T, Chakraborty S, Sarma HD, Venkatesh M, Banerjee S. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. Nucl Med Commun 2009;30:362-7. [PMID: 19282794 DOI: 10.1097/MNM.0b013e328329981a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
15 Schwarz L, Bubenheim M, Gardin I, Huet E, Riachi G, Clavier E, Goria O, Vera P, Scotté M. Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma. World J Surg 2016;40:1941-50. [PMID: 27098539 DOI: 10.1007/s00268-016-3502-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y, Yan Z, Wang K, Wu D, Wu L, Wan X, Yang T, Gao C, Si A, Wang H, Wu M, Lau WY, Chen Z, Shen F. Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2020;5:548-60. [PMID: 32164877 DOI: 10.1016/S2468-1253(19)30422-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
17 Olesinski J, Mithieux F, Guillaud O, Hilleret MN, Lombard-Bohas C, Henry L, Boillot O, Walter T, Partensky C, Paliard P, Valette PJ, Vuillez JP, Borson-Chazot F, Scoazec JY, Dumortier J. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. Ann Nucl Med 2017;31:379-89. [PMID: 28342103 DOI: 10.1007/s12149-017-1165-4] [Reference Citation Analysis]
18 Jia WD. Adjuvant sorafenib after radical liver resection for the treatment of hepatocellular carcinoma: Recent research advances. Shijie Huaren Xiaohua Zazhi 2012; 20(22): 2019-2023 [DOI: 10.11569/wcjd.v20.i22.2019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Gandhi M, Tan SB, Chung Yaw Fui A, Machin D. On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma. Contemp Clin Trials 2015;43:252-9. [PMID: 26111924 DOI: 10.1016/j.cct.2015.06.018] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246-252. [PMID: 21664971 DOI: 10.1016/j.ymeth.2011.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]